Lexaria Bioscience (LEXX) EBITDA Margin (2017 - 2026)
Lexaria Bioscience (LEXX) recorded EBITDA Margin of -7164.01% in fiscal Q2 2026 (quarter ended Feb 28, 2026), down 5584.28 percentage points from -1579.73% a year earlier.
Powered by 
Analysis
Lexaria Bioscience (LEXX) EBITDA Margin (2017 - 2026) Analysis & Trends
For FY2025 (ended Aug 31, 2025), Lexaria Bioscience reported EBITDA Margin of -1683.01%, down 460.25 percentage points from FY2024.
- Annual EBITDA Margin has a five-year change of -400.88 percentage points (FY2020 to FY2025).
- Across earlier fiscal years, EBITDA Margin came in at -1222.75% in FY2024 (+1601.47 pp), -2824.23% in FY2023 (-272.78 pp), -2551.45% in FY2022 (-1780.06 pp) and -771.39% in FY2021 (+510.74 pp).
- The fiscal Q2 2026 figure is the lowest quarterly EBITDA Margin since fiscal Q1 2022.
- On a year-over-year basis, EBITDA Margin rose in three of the last seven quarters, with an average year-over-year change of -670.75 percentage points.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 12523.68 percentage points in fiscal Q1 2023, against a drop of 14001.33 percentage points in fiscal Q1 2022 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Lexaria Bioscience | 3.39 Mn | -12.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Feb 28, 2026 | -7,164.01% |
| Aug 31, 2025 | -1,583.35% |
| May 31, 2025 | -2,137.62% |
| Feb 28, 2025 | -1,579.73% |
| Nov 30, 2024 | -1,444.90% |
| Aug 31, 2024 | -2,603.21% |
| May 31, 2024 | -2,056.96% |
| Feb 29, 2024 | -449.71% |
| Nov 30, 2023 | -733.99% |
| Aug 31, 2023 | -3,393.46% |
| May 31, 2023 | -3,057.45% |
| Feb 28, 2023 | -6,486.37% |
| Nov 30, 2022 | -1,709.41% |
| Aug 31, 2022 | -651.21% |
| May 31, 2022 | -2,401.24% |
| Feb 28, 2022 | -4,641.14% |
| Nov 30, 2021 | -14,233.08% |
| Aug 31, 2021 | -4,109.26% |
| May 31, 2021 | -1,244.09% |
| Feb 28, 2021 | -560.70% |
API Access
Lexaria Bioscience EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LEXX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "LEXX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LEXX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();